Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 2:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Induction Therapy Clear all
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

NCT01418001
View directory record Official record
Conditions
Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Interventions
Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Evanston, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT04919512
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
TAR-200, Cetrelimab
Drug · Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 14, 2026, 2:47 PM EDT
Not yet recruiting Phase 2 Interventional

Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC

NCT07786428
View directory record Official record
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
Pembrolizumab, Paclitaxel (Chemotherapy), Carboplatin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Not applicable Interventional

Adapting Alcohol Behavioral Couple Therapy for Service Members in Post-Deployment

NCT03589521
View directory record Official record
Conditions
Alcohol Abuse
Interventions
ABCT_Military
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Phase 2 Interventional

Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9

NCT00000344
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence

NCT00377299
View directory record Official record
Conditions
Amphetamine Abuse, Amphetamine Dependence, Bipolar Disorder, Major Depressive Disorder
Interventions
Citicoline, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Sep 14, 2026, 2:47 PM EDT
Terminated Phase 1 Interventional

Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC

NCT02987998
View directory record Official record
Conditions
Stage IIIA Non-Small Cell Lung Cancer
Interventions
Cisplatin, Etoposide, Pembrolizumab, Radiation
Drug
Lead sponsor
Nathan Pennell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 14, 2026, 2:47 PM EDT
Active, not recruiting Phase 3 Interventional

Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia

NCT01266044
View directory record Official record
Conditions
Head And Neck Cancer
Interventions
Acupuncture - Group 1, Acupuncture - Group 2, Standard Care, Questionnaire
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

NCT00280787
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, CPT-11, Pegfilgrastim, Conformal radiotherapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 14, 2026, 2:47 PM EDT
Active, not recruiting Phase 3 Interventional

Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl

NCT06089707
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naloxone Nasal Spray
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Phase 4 Interventional

Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation

NCT03787732
View directory record Official record
Conditions
Acute Respiratory Failure, Intubation Complication, Hypotension on Induction
Interventions
Fluid Bolus, No Fluid Bolus
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Burlington, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

NCT01733121
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
21
States / cities
Costa Mesa, California • Fountain Valley, California • Oceanside, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

NCT02779855
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
Interventions
Talimogene laherparepvec, Paclitaxel
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy

NCT04527926
View directory record Official record
Conditions
Opioid-use Disorder, Pregnancy Related
Interventions
STEPuP Intervention, Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,022 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer

NCT00256243
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, GM-CSF, Trastuzumab
Drug
Lead sponsor
Rita Sanghvi, Mehta
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Sep 14, 2026, 2:47 PM EDT
Completed No phase listed Observational

Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia

NCT00085176
View directory record Official record
Conditions
Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions
management of therapy complications, psychosocial assessment and care
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Years to 16 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

NCT00017368
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, sargramostim, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, etoposide phosphate, ifosfamide, isotretinoin, melphalan, thiotepa, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 14, 2026, 2:47 PM EDT
Recruiting Phase 2 Interventional

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

NCT05422690
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Induction Chemotherapy Triplet Therapy, Concurrent Y-90 treatment, Consolidation Doublet Therapy:
Drug · Radiation
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Not applicable Interventional Results available

Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)

NCT01441960
View directory record Official record
Conditions
Neuromuscular Blockade, ECT
Interventions
Succinylcholine, Rocuronium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 14, 2026, 2:47 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas

NCT06025747
View directory record Official record
Conditions
Retroperitoneal Sarcoma, Liposarcoma, Dedifferentiated Liposarcoma
Interventions
Abemaciclib, Computed Tomography, Magnetic Resonance Imaging, Radiation Therapy, Therapeutic Surgical Procedure
Drug · Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 14, 2026, 2:47 PM EDT
Not listed Phase 2 Interventional

Distress Tolerance Treatment for Substance Users

NCT01741415
View directory record Official record
Conditions
Substance Dependence
Interventions
SIDI, SC
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tarpon Springs, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Effectiveness of the Community Reinforcement Approach and Family Training (CRAFT) With American Indians

NCT03203889
View directory record Official record
Conditions
Substance Use Disorders, Family Members
Interventions
CRAFT-AI, TSF-CSO
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Zuni, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

NCT02843074
View directory record Official record
Conditions
Multiple Myeloma
Interventions
elotuzumab, Lenalidomide, Dexamethasone, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Denver, Colorado • Bethesda, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 14, 2026, 2:47 PM EDT
Completed Phase 2 Interventional

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

NCT05150652
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
Interventions
Anastrozole 1mg, Letrozole 2.5mg, Exemestane 25 mg, Tamoxifen
Drug
Lead sponsor
Irada Ibrahim-zada
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 14, 2026, 2:47 PM EDT